A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
Phase 1
40
about 3.7 years
18+
3 sites in NC, TX, VA
What this study is about
This trial is testing a subcutaneous (SC) dose of rilvegostomig. The goal is to determine if this SC dose provides similar exposure levels to the intravenous (IV) form, and to evaluate its safety in adults with advanced solid tumors who have already received standard cancer treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive IV Rilvegostomig
- 2.Take Recombinant Human Hyaluronidase (rHu)
- 3.Take SC Rilvegostomig
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Enzyme Replacements/Modifiers (Enzyme Interactions)
infusion, injection (Injection)
Secondary: Number of participants with adverse events (AEs)